Key Highlights
- Loss was USD 0.86 per share against an estimated USD 1.31 loss, and Revenue of USD 1.39 million met estimates.
- Revenue rose about 25% from USD 1.11 million, and Gross Profit increased USD 239,713 to USD 758,004.
- Cash was USD 5.93 million with Working Capital of USD 4.47 million, and the filing discusses Going Concern conditions.
- The company completed precision, method comparison, interference and usability studies supporting its FDA 510(k) submission.
Intelligent Bio Solutions (NASDAQ:INBS), a maker of a fingerprint-based drug screening system, reported a fiscal first quarter 2027 loss of USD 0.86 per share, narrower than the USD 1.31 estimated loss. Revenue of USD 1.39 million compared with the USD 1.40 million estimate and with USD 1.11 million in the same quarter last year.
Gross profit increased USD 239,713 to USD 758,004 from USD 518,291. Cost of revenue rose USD 40,325 to USD 633,831, which the company attributed to direct Manufacturing labor costs from added factory hiring in the United Kingdom and higher direct overhead.
Contribution margin, a non-GAAP measure of efficiency for direct variable costs such as materials, was USD 1.11 million, or 79.96% of revenue, compared with USD 0.80 million, or 72.11%, a year earlier. The company said the revenue increase was primarily attributable to the addition of 27 new customers and a higher re-order rate for consumables. Revenue is reported on a fiscal year ending June 30, so the September quarter is the first of fiscal 2027. Against a modest revenue base, small changes in customer counts move the percentages noticeably.
Selling, general and administrative expenses decreased USD 127,248 to USD 2,579,641. Marketing expenses were USD 319,086 against USD 624,579 a year earlier.
Liquidity and Going Concern Evaluation
Cash and cash equivalents were USD 5,929,871 at September 30, with working capital of USD 4,466,995. The filing states that management evaluated whether conditions raise substantial doubt about the company's ability to continue as a going concern within one year of issuance. The company has an at-the-market offering agreement entered into in September 2024 with Ladenburg Thalmann.
The legal proceedings item states the company is not currently engaged in any material legal proceedings. The filing also notes no material changes to risk factors beyond those disclosed in its annual report, with one exception it describes.
FDA Submission Progress
During the quarter, the first of its fiscal year ending June 30, 2027, the company completed precision testing, a method comparison study, an interference study and a usability study for the Intelligent Fingerprinting Drug Screening System, supporting its FDA 510(k) submission for market clearance for detection of the opiate codeine. The interference study evaluated whether external contaminants commonly encountered in daily life and workplace environments affect accuracy and reliability, and it was described as the most comprehensive evaluation in the company's 510(k) clinical program.
On July 23, 2026 the company announced it had addressed all Cybersecurity and software-related review items for the upcoming submission.
Items to Follow
The timing of the 510(k) submission, new customer additions, consumables re-order rates and the cash balance relative to quarterly spending are the figures to follow.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...